Introduction:
Transformed cells retain the ability to undergo premature or replicative senescence in response to various stimuli. Senescent cells undergo irreversible cell cycle arrest and display characteristic phenotypic alterations, including an enlarged and flattened morphology and expression of senescence-associate β -galactosidase activity (SA-β-gal) (Dimri et al., 1995) .
Some anticancer agents induce a rapid, non-telomere-dependent form of senescence, often termed premature senescence, in cancer cells at concentrations that do not cause acute cell death in vitro or in vivo (Hornsby, 2007) . These agents include PI-3 kinase inhibitors (Collado et al., 2000) , retinoic acid (Roninson and Dokmanovic, 2003) , microtubulestabilizing agents (Arthur et al., 2007) , Sirt1 (Ota et al., 2006) and DNA topoisomerase inhibitors (Michishita et al., 1998) , doxorubicin (Vigneron et al., 2005) and cisplatin (Varna et al., 2009 ). Induction of SA-β -gal staining after chemotherapy has been observed in cells obtained from patients with breast cancer (te Poele et al., 2002) and senescence-like growth arrest has been proposed as a determinant of in vivo tumor response to both selective chemotherapeutic agents and ionizing radiation (Kahlem et al., 2004) .
Multiple mechanisms have been implicated in the induction of senescence, including telomere shortening induced by inhibition of TERT activity (Kim et al., 2003) , induction of p53 (reviewed in Ref (Chang et al., 1999) ), increased expression of cyclin-dependent kinase inhibitors such as p16 INK4a (Uhrbom et al., 1997) , p21 and p27 (Collado et al., 2000) , and dephosphorylation of Rb (Xu et al., 1997) .
Cyclopentenyl cytosine (CPEC) is an analogue of cytidine (Kang et al., 1989 ) and enters cells preferentially through the equilibrative nucleoside transporters including ENT1 and ENT2 (Huang et al., 2004) . Intracellularly, CPEC is metabolized into its mono-, di-, and triphosphate forms (Kang et al., 1989) . In its triphosphate form, it serves as a specific
noncompetitive inhibitor of CTP synthetase, which catalyses the conversion of UTP to CTP as the predominant pathway for CTP synthesis in proliferating cells (Schimmel et al., 2007) .
As a result, the intracellular CTP pool is rapidly depleted (Huang et al., 2004; Kang et al., 1989) . Previous studies have established the anti-tumor effects of CPEC using a number of tumor cell lines (Schimmel et al., 2007) and several tumor models (Schimmel et al., 2007; Van Bree et al., 2009 ) . In addition, CPEC was shown to act at nanomolar concentrations in vitro as a chemosensitizer to enhance the anti-cancer effects of several nucleoside analogues such as AraC (1-β-D-arabinofuranosylcytosine) and 2',2'-difluorodeoxycytidine (dFdC, gemcitabine) in a variety of tumor cell lines (Schimmel et al., 2007) , although no enhanced efficacy of CPEC was found when combined with gemcitabine and radiation in two animal tumor models (Van Bree et al., 2009 ).
In the present study, we have found that CTP depletion results in a pronounced nucleolar stress response. The effects of CTP depletion on cell proliferation, differentiation, apoptosis, and cellular senescence and related signaling pathways were assessed. These data provide evidence that nucleolar stress triggered by CTP depletion serves to regulate critical events leading to the induction of senescence or differentiation/apoptosis depending on the p53 status of the cell.
Materials and methods:
Cell culture conditions and reagents used. The p53 wild-type MCF-7 human breast tumor cell line and p53 mutant MDA-MB-231 cells were obtained from ATCC. U2OS cells stably expressing EGFP-tagged NS (EGFP-NS) have been described previously (Huang et al., 2009 Assay of senescence-associated β -galactosidase activity (SA-β -gal). SA-β -gal staining was performed as previously described (Dimri et al., 1995) . At the appropriate times after treatment, cells were washed twice in PBS, fixed in 2% formaldehyde/0.2% glutaraldehyde for 5 min at room temperature, washed again in PBS, and incubated with β -galactosidase Mounting Medium (Sigma-Chemical Co., USA) and examined using fluorescent microscopy.
Western blotting. Immunoblot analysis was performed as previously described (Huang et al., 2009 ).
Apoptosis assay. Quantitation of apoptosis by annexin V/ propidium iodide (PI) staining was performed as described previously (Huang et al., 2002) . Briefly, MCF-7 cells were transfected with p53 Smartpool siRNA (100 nM) and control siRNA (100 nM) by Amaxa
Electroporation. 24 h after electroporation, cells were exposed to CPEC or DMSO vehicle control for 5 days. Apoptotic cell death was determined using the BD ApoAlert Annexin V-FITC Apoptosis Kit (BD Biosciences, USA) according to the manufacturer's instructions, and cells were analyzed using flow cytometry.
Oil Red staining. Cells grown in 12 well plates were washed with PBS, fixed with paraformaldehyde, washed three times with PBS, and stained with Oil Red O (Sigma Chemical) for 10 min according to published procedures (Ryden et al., 2003) . after 5 days (Fig. 1A, 1B) . Nutlin-3a, an inhibitor of Mdm2, was used as a positive control (Fig. 1C) . In contrast, no increase in SA-β-gal positivity over background was observed in MDA-MB-231 cells treated with either CPEC or Nutlin-3a (Fig. 1A, 1C) . Next, we investigated whether the growth arrest found in MDA-MB-231 cells was attributable to either quiescence or differentiation. CPEC-treated MDA-MB-231 cells were stained with oil-red to assay for lipid droplets as a reflection of differentiation of breast cancer cells (Adan et al., 2003) . As shown in Fig. 2A , over 80% of MDA-MB-231 cells exhibited a marked increase in the presence of lipid droplets after 5 days of CPEC treatments, whereas MCF-7 cells did not stain with oil-red (Fig. 1 ). The addition of cytidine, previously shown to replenish intracellular CTP pools through its phosphorylation to CMP via uridine/cytidine kinase (Huang et al., 2004) , almost completely prevented both the differentiation of MDA-MB-231 cells ( Fig. 2A ) and the senescence of MCF-7 cells ( 3A ) while decreasing the extent of BrdU incorporation into DNA (supplemental Fig. 2B and 3B ).
Despite the induction of an increase in the S-phase cell population in both cell lines at 48 h, 5 days of CPEC treatment resulted in cell cycle arrest in both the S and G2 phases in MCF-7
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induced both a G1 and a G2 arrest in MCF-7 cells (Fig. 3A and 3B ). In both cell lines, a sustained reduction in BrdU incorporation (from 37.5% to 12.8%-23.7% in MCF-7 cells and from 20.2% to 2.9-11.1% in MDA-MB-231 cells) was observed after 5 days after CPEC treatment (Fig. 3B, 4B) , correlating with the lack of proliferation at this time point.
Effect of CPEC on activation of p53, p21, and γ-H2AX. It has been well established that downstream targets of p53 are able to trigger replicative/premature senescence (Collado et al., 2007) . p21 (Waf1/Cip1) is a potent cyclin-dependent kinase inhibitor that is transcriptionally regulated by p53 and appears to be central to both p53-dependent (Collado et al., 2007) and p53-independent senescence. In MCF-7 cells, CPEC treatment resulted in a sustained increase in both p53 and p21 expression. In addition, the expression of Mdm2, another p53 target, was induced by CPEC treatment in MCF-7 cells (Fig. 5A ) while β -actin expression remained constant. A moderate increase in the Mdm2 protein level was also detected in p53-mutant MDA-MB-231 cells, suggesting there may be a p53 independent regulation of Mdm2 (Fig. 5B) . The levels of p21 were unchanged in these cells (Fig. 5B) . As expected, a similar pattern of p53 and Mdm2 accumulation was observed in nutlin3 treated MCF-7 cells (supplemental Fig. 4 ). Phosphorylated γ-H2AX, an indicator of DNA damage response, increased dramatically in MDA-MB-231 cells after 24 h of CPEC exposure, but did not change significantly in comparison to control in MCF-7 cells ( Fig. 5A and 5B). reduced the level of endogenous p53 protein by well over 80%. Depletion of p53 using the siRNA approach completely prevented CPEC-induced elevation of Mdm2, (Fig. 6A ) and significantly reduced the degree of senescence (P<0.001) ( Fig. 6B and 6C) , while increasing the percentage of Annexin V and PI double positive staining cells from 21.7 to 36.0% (Fig.   6D ). An increased percentage of Annexin V and PI double positive staining cells (73.5%-77.9% of cells) suggestive of apoptosis was also observed in p53-null HL60 cells after exposure to CPEC at concentrations as low as 0.125 µM for 32 h (Fig. 6E) . To further determine whether cell death was due to apoptosis, DNA was isolated from control or CPEC- NS and nucleolin in this cell line as well (Fig. 7C, Supplemental Fig. 6 ). Previous data have demonstrated that inhibition of Pol I by actinomycin D results in translocation of nucleolar PAF53 and TIF-IA, two components of the Pol I complex, to the nucleolar caps (Huang et al., 2008) , a phenomenon reflecting "nucleolar stress". CTP depletion also induces similar translocation of TIF-IA and PAF53 from the nucleolus to the nucleolar caps (Supplemental Fig. 6 ), further supporting its inhibitory effect on Pol I activity through CTP depletion.
Discussion:
p53 is a central mediator of senescence in response to a variety of stress stimuli including DNA damage, oncogene over-expression, telomere dysfunction, and oxidative damage, as reviewed in (Collado et al., 2007) . Our finding that CPEC induces senescence in MCF-7 cells expressing wild-type p53 in conjunction with sustained increases in p53 and p53-dependent Mdm2 and p21 expression while senescence is prevented by p53 depletion strongly implicates p53 accumulation as a prerequisite for the senescent phenotype.
Mdm2 maintains p53 at low levels by actively controlling its nuclear export (Freedman and Levine, 1998) , transactivation (Momand et al., 1992) , ubiquitination and proteosomedependent degradation (Honda et al., 1997) , and translation (Ofir-Rosenfeld et al., 2008) . The
Mdm2 gene is also a transcriptional target of p53 and an increase in p53 expression upon stress leads to activation of Mdm2 transcription (Barak et al., 1993) . This Mdm2-p53 autoregulatory loop normally maintains p53 at low levels in non-stressed cells. Our evidence that depletion of cellular CTP leads to stabilization of wild-type p53 in the presence of proteins include ARF (Bothner et al., 2001) , the ribosomal large-subunit proteins L5, L11, L23 (Lindstrom et al., 2007) , the nucleolar protein nucleostemin (Dai et al., 2008; Meng et al., 2008) and very recently, the ribosomal small subunit protein 7 (S7) (Zhu et al., 2009) . Of interest, most of those Mdm2 binding proteins are localized predominantly in the nucleolus under physiologic conditions, but are released from nucleolus into nucleoplasm in response to various stressors, including agents such as low dose actinomycin D that inhibit Pol I. We have previously shown that depletion of GTP induced by inhibition of its de novo synthetic pathway similarly induces a nucleolar stress response (Huang et al., 2008) . In the present study, CPEC-mediated CTP depletion also results in nucleolar stress, causing nucleoplasmic translocation of nucleostemin and other nucleolar proteins including nucleolin and NPM1
and a simultaneous translocation of TIF-IA and PAF53, two components of the Pol 1 complex, to the nucleolar caps. Segregation of Pol I components into these fibrillar caps is a characteristic feature of inhibition of RNA Polymerase I-mediated transcription (Shav-Tal et al., 2005) . It is reasonable to conclude that the release of nucleolar Mdm2-binding proteins triggered by CTP depletion is, at least in part, responsible for the increased stability of p53.
The lack of ARF expression in MCF-7 cells rules out a role for ARF in the observed p53 activation (Della Ragione et al., 1995) . However, the presumed release of other Mdm2-binding proteins including a number of small ribosomal subunit proteins is very likely to have played a role.
Cells entering senescence undergo irreversible cell cycle arrest, most often in the G1/S and/or G2/M phases of the cell cycle (Sugrue et al., 1997) . Inducible expression of wild-type p53 in EJ bladder carcinoma cells, which have lost functional p53, was shown to trigger the rapid onset of G1 and G2/M senescent growth arrest associated with p21 up-regulation (Sugrue et al., 1997) . Supporting a role for p53 in mediating G2 cell cycle arrest, nutlin-3a
and CPEC both induce p53 accumulation and G2 arrest in MCF-7 cells that undergo
senescence (Fig 3A, 3B , and supplemental Fig. 4 ), but not in MDA-MB-231 cells expressing mutated p53 (Fig 4A and 4B) . p16 INK4a can also initiate senescence through inhibiting the cyclin-dependent kinases cdk4 and cdk6 (Uhrbom et al., 1997) . However, MCF-7 and MDA-MB-231 cells both have homozygous deletions of p16 INK4 (Della Ragione et al., 1995) , ruling out involvement of this protein as an effector of CPEC-induced senescence or differentiation.
The increase in p-H2AX caused by CPEC treatment in MDA-MB-231 cells reflects a DNA damage response, most likely due to concomitant depletion of the cytidine deoxyribonucleotide pool. Under similar conditions, other deoxyribonucleotides are misincorporated into DNA, resulting in a similar DNA damage response (Schimmel et al., 2007) .
The observation that depletion of endogenous p53 switched the cell fate of MCF-7 cells from a senescent to an apoptotic fate indicates that activation of the p53 pathway plays an essential role in inducing the senescence phenotype. It has been well documented that p53 mutations such as R175H, R273H, V135A mediate resistance to drug-induced apoptosis through suppression of procaspase-3 and caspase-3 (Lotem and Sachs, 1995; Tsang et al., 2005; Wong et al., 2007) . These data raise the possibility that the expression of mutated p53 primes MDA-MB-231 cells for differentiation in response to nucleolar stress induced by CTP depletion, whereas p53 deficiency primes cells for apoptosis.
Although CPEC alone has established anti-tumor effects in a variety of cancer model systems, both in vitro and in vivo (Schimmel et al., 2007; Van Bree et al., 2009 ), severe cardiovascular toxicity was observed in five of 26 patients with solid tumors treated in a phase I clinical trial. However, this toxicity occurred only at the highest doses administered with corresponding steady-state plasma CPEC concentrations varying between 1.8-2.75 µM (Politi et al., 1995) . Our data, in conjunction with those of others (Huang et al., 2004;  M O L # 7 0 2 8 4 1 6 Schimmel et al., 2007) , indicate that CPEC induces senescence, differentiation, or apoptosis at nanomolar concentrations in tumor cell lines in vitro. In theory, the effects of CPEC against tumors could be mitigated by cytidine present in human plasma. However, the physiological concentrations of uridine (5 µM) or cytidine (0.5 µM) in human plasma are not sufficient to prevent cell cycle arrest induced by nanomolar concentration of CPEC (50 nM) (Huang et al., 2004) . In contrast to transformed cells, primary MEF cells expressing wildtype p53 are relatively resistant to CPEC treatment at concentrations up to 1µM (data not shown). It is quite possible that CPEC is selectively toxic to transformed cells due to increased uptake as the result of the increase in nucleoside transporters identified in tumor cells (Rauchwerger et al., 2000) . Whether the intracellular metabolism of CPEC to its triphosphate form is also enhanced in some tumor cells through an increase in uridinecytidine kinase activity (Kang et al., 1989) or a decrease in nucleotidase activity has not been investigated. If CPEC is to be reconsidered as an antineoplastic agent, especially given evidence of activity in p53-deficient cells, it will be important to investigate its relative uptake and metabolism in both tumor and normal tissue. A clinical resurgence of this drug would also require in vitro and in vivo studies to determine the optimal plasma concentration of CPEC that results in selective toxicity for tumor cells. with Annexin-V and PI followed by flow cytometric analysis. 
